VilonВилон
What the studies found
Observational study · 2007
Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus
- Immune and coagulation markers
- Reported changes during adjunctive Vilon treatment; numerical effect sizes not supplied
Adjunctive Vilon in type 1 diabetes was associated with immune and coagulation-marker changes, including antithrombin III, protein C and fibrinolysis. No autoimmune disease-modifying effect is established.
Study notes · methods, sources and limitations
Participants or model Type-1 diabetes patients receiving adjunctive care
Important limitations
- The abstract leaves enrollment and allocation unclear. Its findings cannot establish an alternative to insulin. Full methods, adverse-event reporting and independent replication remain to be appraised.
- Type 1 diabetes report, not proof of beta-cell preservation, restored tolerance or replacement of insulin. Possible overlap with the 2006 publication prevents pooling.
Advances in gerontology = Uspekhi gerontologii 20(2):106-115. PMID 18306698 · Journal publication
Comparison in people · 2008
Vilon after complicated appendicitis
Study of multiple preparations
- Mean hospitalization
- 18.8 ± 0.6 days (five days, n = 30) and 19.0 ± 0.5 days (ten days, n = 10)Adjunct sample: 40 across both groups. Standard care: 24.2 ± 0.6 days (n = 10).
- TNF-α before → after
- 447 ± 20 → 115 ± 9 pg/mL (separate n = 25 subset)Within-group p < 0.001 in Table 3
In this small comparison, mean stay was 5.4 and 5.2 days shorter with Vilon plus standard care. The standard-care group averaged 24.2 days.
Study notes · methods, sources and limitations
Participants or model 84 adults aged 18–42: 12 with uncomplicated appendicitis and 72 with postoperative wound infection. Of the 72, 62 received a peptide adjunct. Thirty healthy volunteers were a laboratory reference group.
Design Comparison of standard care and peptide adjuncts after postoperative wound infection. The paper measured serum cytokines by immunoassay and compared immune markers before and after treatment.
Important limitations
- The study had small, unequal groups and unclear treatment assignment. The differences are unadjusted.
- Small, unequal groups and unclear treatment assignment leave confounding unresolved. The article does not establish that Vilon was superior or equivalent to the other adjuncts. The Vilon hospital groups totaled 40. The cytokine table included 25, with no breakdown by treatment duration. The hospitalization paragraph prints p < 0.01 after each mean without clearly specifying a contrast. No systematic adverse-event table or quantified wound-healing rates were recovered.
- Vilon showed the largest within-group TNF-α decrease. Hospitalization means were close among the four adjunct groups. Neither outcome establishes a comparative treatment effect.
Medical Immunology. 2008;10(4–5):455–462. · Original clinical journal article
Animal research · 2008
Vilon in the separate adult-hypoxia arm
Study of multiple preparations
- Respiration arrest
- 149 ± 47 secondsSaline 72 ± 10 seconds; n=10/groupp<0.08; not a demonstrated p<0.05 difference
- Adult mortality
- 20%Saline 10%; very small groups, no verified mortality difference test
In adult male rats, Vilon was associated with 149 ± 47 seconds to respiration arrest versus 72±10 with saline. This arm did not expose pregnant animals to Vilon.
Study notes · methods, sources and limitations
Participants or model Pregnant rats exposed to hypoxia on gestation day 10; separate adult-male experiment, n=10/group; offspring open-field strata n=6, 11, 9 and 12
Design Two distinct experiments: five-day pretreatment in adult males, and maternal Pinealon after gestation-day-10 hypoxia. Offspring cerebellar cells tested at day 12; open-field behavior at four weeks, stratified by maternal hypoxia sensitivity.
Important limitations
- Only Pinealon was studied in the maternal arm of this publication. Adult hypoxia findings are adjacent context, not pregnancy-safety evidence.
- Animal injury experiments do not establish human pregnancy safety. Epitalon, Vilon and Vesugen were tested only in the adult-male arm of this paper. Number of pregnant dams, randomization, masking and litter-adjusted statistics are not established. Offspring are not independent maternal exposures. Table 1 mortality conflicts with the prose; do not convert the latter into a verified excess risk. Vilon and Epitalon respiration findings marked p<0.08 are not demonstrated p<0.05 results. The paper prints an Epitalon sequence ending in Arg; established Epitalon identity is Ala-Glu-Asp-Gly. That apparent source error is retained as an identity warning.
Doklady Biological Sciences. 2008;418:7–10; Russian original Doklady Akademii Nauk 418(3):419–422. PMID 21249538 · Original journal publication
About Vilon
Names in this research collection
KE
A short peptide containing two amino acids, listed in the 2013 bioregulator catalogue in connection with tissue regeneration. This is a research target, not an established treatment benefit.
Identity / background source ↗
Research background
Defined Lys–Glu (KE) dipeptide with historical adjunct-treatment reports in type 1 diabetes and separate laboratory research. Immune and coagulation-marker findings do not establish autoimmune disease modification.
Autoimmune research: disease-specific findings, immune effects and open questions ↗
Pregnancy and offspring research
In adult male rats, Vilon was associated with 149 ± 47 seconds to respiration arrest versus 72±10 with saline. This arm did not expose pregnant animals to Vilon.
Only Pinealon was studied in the maternal arm of this publication. Adult hypoxia findings are adjacent context, not pregnancy-safety evidence.
Reported findings and methods ↗ · Pregnancy research: full evidence review and archive ↗
Conference sources and research collaborators ↗
More study findings
Animal research · 2006
Age and baseline anxiety in Lysenko’s peptide stress models
Study of multiple preparations
- High-anxiety young rats
- Vilon and GVS-111 were highlighted in the author’s conclusionsOriginal group-level numerical estimates and doses still need retrieval.
- Stress-response direction
- Favorable and unfavorable responses describedThe author discusses this for GVS-111 and an experimental preparation called NKT. NKT identity remains unresolved.
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
Study notes · methods, sources and limitations
Participants or model Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
Design Hypokinesia, hypoxia and exertion models, with behavioral, immune and oxidative endpoints. Twenty-four-hour hypokinesia was one stress protocol.
Important limitations
- Potential overlap with narrower author-network dissertations, including Morgul and Rudenko. Outcomes cannot be pooled or assigned to humans.
- A mechanistic program on stress response. The dissertation-level conclusion does not isolate all preparation-specific effects.
Doctoral dissertation, 244 pp., introduction and conclusions · Doctoral dissertation, 244 pp., introduction and conclusions
Review of earlier studies · 2026
From thymus extracts to synthetic thymomimetics
Study of multiple preparations
- Thymomimetic research
- The authors summarize evidence from different thymic compounds and discuss changes in neutrophil phenotype and function in studies of Imunofan.
The review traces the move from thymus-derived mixtures to defined compounds and summarizes neutrophil phenotypes and functional assays reported for the thymopoietin-derived hexapeptide Imunofan.
Study notes · methods, sources and limitations
Participants or model Review of laboratory and clinical literature on thymic peptides.
Important limitations
- Cell markers, laboratory findings and outcomes from combination care answer different questions. The review does not validate efficacy across thymic peptides.
- Secondary synthesis. No new clinical cohort or pooled effect estimate.
Adaptive Medical Immunology and Public Health Issues. 2026;2(1):6–19. · Narrative review
Lab research · 2012
Epitalon and Vilon in rat pinealocyte culture
Study of multiple preparations
- Epitalon and melatonin
- Higher melatonin in culture medium reported
- AANAT and phosphorylated CREB
- Increases with Epitalon; stronger expression with norepinephrine plus peptides
The abstract reports increased AANAT and phosphorylated CREB and higher culture-medium melatonin with Epitalon. It describes stronger marker expression when norepinephrine was added with the peptides.
Study notes · methods, sources and limitations
Participants or model Cultured rat pinealocytes.
Design Rat pinealocytes were exposed to Epitalon or Vilon, with norepinephrine in additional conditions. The study assessed AANAT, phosphorylated CREB and melatonin in culture medium.
Important limitations
- The abstract does not give arm-level magnitudes, sample sizes or concentrations. It attributes the standalone melatonin increase to Epitalon. A culture response cannot establish improved sleep in people.
Bulletin of Experimental Biology and Medicine. 2012;153(2):255–258. PMID 22816096. · Indexed abstract
Observational study · 2006
Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age
- Coagulation / fibrinolysis
- Reported improvement, with less pronounced effects in older, severely affected patients
The abstract reports coagulation and fibrinolysis changes during adjunctive Vilon treatment in type 1 diabetes, with weaker responses in older patients with severe disease. These are surrogate outcomes.
Study notes · methods, sources and limitations
Participants or model Type-1 diabetes patients of different ages
Important limitations
- The study may share participants with the 2007 diabetes publication. Full methods, adverse-event reporting and independent replication remain to be appraised.
- Allocation, sample size and independent effect size are not established from the abstract. Biomarkers are not disease-modifying outcomes; cohort overlap remains unresolved.
Advances in gerontology = Uspekhi gerontologii 19():107-115. PMID 17152731 · Journal publication
Lab research · 2004
Effects of short peptides on lymphocyte chromatin in senile subjects
Study of multiple preparations
- Chromatin readouts
- Ribosomal-gene activation and decondensation reported; no numerical treatment effect supplied
Five short peptides increased ribosomal-gene activity and altered condensed chromatin in sampled leukocytes. Epitalon, Livagen and Prostamax changed chromosome-1 pericentromeric chromatin; Epitalon and Livagen also changed chromosome 9.
Study notes · methods, sources and limitations
Participants or model Leukocytes sampled from people aged 75–88 years and exposed to peptides in culture.
Design Leukocytes sampled from people aged 75–88 years and exposed to peptides in culture.
- Donor ages
- 75–88 years
Important limitations
- People donated cells; they were not treated in a clinical trial. Chromatin changes do not establish rejuvenation or longer life. Related chromatin-program publications may overlap.
Bulletin of experimental biology and medicine 2004 · Journal publication
Lab research · 2022
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Study of multiple preparations
- Inflammatory response
- Reduced LPS-stimulated TNF/IL-6 in differentiated cells; reduced monocyte adhesion
- Chonluten cell response
- Reduced monocyte TNF; an apoptotic fraction also observed
Five preparations reduced LPS-induced TNF and IL-6 expression in differentiated THP-1 cells and reduced adhesion to activated endothelial cells. Chonluten also reduced monocyte TNF release; the full text notes an apoptotic cell fraction with Chonluten.
Study notes · methods, sources and limitations
Participants or model THP-1 leukemia-derived monocytes, differentiated macrophages and an activated HUVEC endothelial adhesion model.
Design THP-1 leukemia-derived monocytes, differentiated macrophages and an activated HUVEC endothelial adhesion model.
- Test concentration
- 100 ng/mL per preparation; LPS 100 ng/mL in monocyte/macrophage experiments
Important limitations
- A cell-line experiment, with peptides tested individually. No patient treatment or clinical anti-inflammatory effect was measured. Numerical cytokine reductions are shown graphically rather than supplied as exact data tables.
International journal of molecular sciences 2022 · Journal publication
Research record · 2014
Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process
Study of multiple preparations
- Crystagen response
- B-cell activation reported; no aging-spleen cell renewal
- Other peptide responses
- Vilon: reduced T-helper apoptosis; Thymogen: B-cell proliferation with less apoptosis
Crystagen activated B-cell measures but did not cause renewal of the aging spleen. Vilon was associated with lower T-helper-cell apoptosis; Thymogen with lower apoptosis and increased B-cell proliferation.
Study notes · methods, sources and limitations
Participants or model Experimental aging-spleen work; species and assay design not specified in the indexed abstract.
Design Experimental aging-spleen work; species and assay design not specified in the indexed abstract.
Important limitations
- The abstract does not establish the experimental model sufficiently to classify this as a human study or a specific animal/cell design. Commercial product equivalence is unverified.
Advances in gerontology = Uspekhi gerontologii 2014 · Journal publication
- Compound class
- Bioregulator
- Research collection
- Peptide bioregulation · editorial grouping
- Research institutions
- No institutional affiliation recorded
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Two historical type 1 diabetes reports; possible cohort overlap
Study methods
KE cell experiments and thymus-composition analysis
Independent replication
New citations are not automatically independent replication; shared programs and translated reports require cohort checks
Source access
New indexed primary abstracts and/or report reproductions linked; review depth shown per source
Safety evidence
Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved
Open a topic for the evidence assessment.
Patents and claimed inventions
These 2 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
The 2013 Khavinson–Solovyev review cites US6139862 for Vilon, but that US grant claims Ile-Trp preparations rather than Lys-Glu. The Lys-Glu mapping here uses the directly checked RU2139085 claim instead. Original source ↗
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Linked sources
Explore the research map and unresolved leads ↗
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗